

Adapta[™] Screening Protocol and Assay Conditions
Revised 19-Jun-2017

Page 1 of 11

ASSAY THEORY	2
ADAPTA ASSAY CONDITIONS	3
ADAPTA ASSAY CONTROLS	4
ADAPTA DATA ANALYSIS	5
KINASE-SPECIFIC ASSAY CONDITIONS	6
CAMK1 (CaMK1)	Error! Bookmark not defined
CDK4/cyclin D1	Error! Bookmark not defined
CDK4/cyclin D3	Error! Bookmark not defined
CDK7/cyclin D1	Error! Bookmark not defined
CDK9/cyclin T/mna11	Error! Bookmark not defined Error! Bookmark not defined
CHUK (IKK alpha)	Error! Bookmark not defined
DAPK1	Error! Bookmark not defined
GSG2 (Haspin)	
IRAK1	Error! Bookmark not defined
LRRK2	Error! Bookmark not defined
LRRK2 FL	Error! Bookmark not defined
LRRK2 G2019S	Error! Bookmark not defined
LRRK2 G2019S FL	Error! Bookmark not defined Error! Bookmark not defined
LRRK2 I2020T	
NUAK1 (ARK5)	Error! Bookmark not defined
PI4K2A (PI4K2 alpha)	
PI4K2B (PI4K2 beta)	Error! Bookmark not defined
PI4KA (PI4K alpha)	Error! Bookmark not defined
PI4KB (PI4K beta)	Error! Bookmark not defined
r indeza (r idn-ez alpita)	LITOI: BOOKIIIAI K HOT GEILIEG
PIK3C2B (PI3K-C2 beta) PIK3C2B (PI3K-C2 beta)	Error! Bookmark not defined
PIK3C2G (PI3K-C2 gamma)	Error! Bookmark not defined
PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha)	
PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha)	Error! Bookmark not defined
PIK3CA/PIK3R1 (p110 alpha/p85 alpha)	Error! Bookmark not defined
PIK3CA/PIK3R3 (p110 alpha/p55 gamma)	Error! Bookmark not defined
PIK3CB/PIK3R1 (p110 beta/p85 alpha)	Error! Bookmark not defined
PIK3CB/PIK3K2 (p110 deta/p85 deta)	Error! Bookmark not defined
PIK3CD/PIK3R1 (f010 delta/p85 alpha)	Error! Bookmark not defined Error! Bookmark not defined
PIK3CG (p110 gamma) PIP4K2A	Error! Bookmark not defined
PIP5K1A	Error! Bookmark not defined
PIP5K1B	Error! Bookmark not defined
PIP5K1C	Error! Bookmark not defined
PIP5K1C	Error! Bookmark not defined
SPHK2	Error! Bookmark not defined



SelectScreen™ Biochemical Kinase Profiling Service
Adapta™ Screening Protocol and Assay Conditions Revised 19-Jun-2017

Page 2 of 11

Assay Theory

The Adapta universal kinase assay is a homogenous, fluorescent based immunoassay for the detection of ADP. In contrast to ATP depletion assays, the Adapta assay is extremely sensitive to ADP formation such that a majority of the signal change occurs in the first 10-20% conversion of ATP to ADP. This makes the Adapta universal kinase assay ideally suited for use with low activity kinases.

The principle of the Adapta universal kinase assay is outlined below. The assay itself can be divided into two phases: a kinase reaction phase, and an ADP detection phase. In the kinase reaction phase, all components required for the kinase reaction are added to the well, and the reaction is allowed to incubate for 60 minutes. After the reaction, a detection solution consisting of a europium labeled anti-ADP antibody, an Alexa Fluor™ 647 labeled ADP tracer, and EDTA (to stop the kinase reaction) is added to the assay well. ADP formed by the kinase reaction (in the absence of an inhibitor) will displace the Alexa Fluor 647 labeled ADP tracer from the antibody, resulting in a decrease in the TR-FRET signal. In the presence of an inhibitor, the amount of ADP formed by the kinase reaction is reduced, and the resulting intact antibody-tracer interaction results in a high TR-FRET signal.




Figure 1. Schematic of the Adapta Universal Kinase assay

ADP formation is determined by calculating the emission ratio from the assay well. The emission ratio is calculated by dividing the intensity of the tracer (acceptor) emission by the intensity of the Eu (donor) emission at 615 nm as shown in the equation below.



SelectScreen™ Biochemical	Kinase	Profiling	Service
---------------------------	--------	------------------	---------

Adapta™ Screening Protocol and Assay Conditions

Revised 19-Jun-2017

Page 3 of 11

Since the Adapta technology measures ADP formation (i.e. conversion of ATP to ADP) it can be used to measure any type of ATP hydrolysis, including intrinsic ATPase activity of kinases. In this case, the substrate is water, not a lipid or peptide. The SelectScreen service screens CHUK in this way, so a substrate is not included in the kinase reaction. A reference for using intrinsic ATPase activity to screen for kinase inhibitors is provided below.

Kashem, MA et al. (2007) J. Biomol. Screen. 12(1):70-83

Adapta Assay Conditions

Test Compounds

The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the starting concentration of the customer's choosing.

Substrate/Kinase Mixtures

All Substrate/Kinase Mixtures are diluted to a 2X working concentration in the appropriate Kinase Buffer (see section *Kinase Specific Assay Conditions* for a complete description).

ATP Solution

All ATP Solutions are diluted to a 4X working concentration in water.

ATP Km apparent is previously determined using a radiometric assay except when no substrate is available in which case an Adapta assay is conducted.

Detection Mix

The Detection Mix is prepared in TR-FRET Dilution Buffer. The Detection mix consists of EDTA (30 mM), Eu-anti-ADP antibody (6 nM) and ADP tracer. The detection mix contains the EC $_{60}$ concentration of tracer for 5-150 μ M ATP.

Assay Protocol

Bar-coded Corning, low volume, white 384-well plate (Corning Cat. #4512)

- 100 nL 100X Test Compound in 100% DMSO
- 2. $2.4 \mu L 30 \text{ mM HEPES}$
- 3. $2.5 \mu L 4X$ ATP Solution
- 4. 5 µL 2X Substrate/Kinase Mixture
- 5. 30-second plate shake
- 6. 1-minute centrifuge at 1000 x g
- 7. 60-minute Kinase Reaction incubation at room temperature
- 8. 5 μL Detection Mix
- 9. 30-second plate shake
- 10. 1-minute centrifuge at 1000 x g
- 11. 60-minute Detection Mix equilibration at room temperature
- 12. Read on fluorescence plate reader and analyze the data



SelectScreen™ Biochemical Kinase Profi	ling Service		
Adapta™ Screening Protocol and Assay Conditions Revised 19-Jun-2017			
	Page 4 of 11		

Adapta Assay Controls

The following controls are made for each individual kinase and are located on the same plate as the kinase:

0% Conversion Control (100% Inhibition Control)

The maximum Emission Ratio is established by the 0% Conversion Control (100% Inhibition Control), which contains no ATP in the kinase reaction and therefore exhibits no kinase activity. After addition of the Detection Mix containing EDTA, ATP is added to these wells. ATP addition is required for the 0% conversion controls wells because the ADP antibody binds ATP with low affinity. The ATP in wells with maximum kinase inhibition will displace the ADP tracer slightly, though much less efficiently than ADP.

100% Conversion Control

The 100% Conversion Control wells contain ADP instead of ATP and are designed to allow for the calculation of percent ATP conversion.

The 0% Conversion and 100% Conversion Controls allow one to estimate the percent ATP Conversion achieved in a specific reaction well. Control wells do not include any kinase inhibitors.

0% Inhibition Control

The minimum Emission Ratio in a screen is established by the 0% Inhibition Control, which contains active kinase. This control is designed to produce < 40%* ATP conversion in the Kinase Reaction.

*The range of ATP conversion allowed is different for each kinase and set in the linear region.

Known Inhibitor

A known inhibitor control standard curve, 10 point titration, is run for each individual kinase on the same plate as the kinase to ensure the kinase is inhibited within an expected IC₅₀ range previously determined.



SelectScreen™ Biochemical Kinase Profiling Service				
Adapta [™] Screening Protocol and Assay Conditions Revised 19-Jun-2017				
	Page 5 of 11			

Adapta Data Analysis

The following equations are used for each set of data points:

We run Adapta assays in the linear range determined for each kinase. Full ATP/ADP standard curves are run during validation to define this range. In addition, ATP/ADP standard curves are used to calculate the percent ATP conversion of each sample.

	Equation				
Emission Ratio	AF647 Emission (665 nm) Europium Emission (615 nm)				
% Conversion	$\left\{ \begin{array}{c} EC_{50 \ SC} \\ \hline \left(\begin{array}{c} Top_{\ SC} - Bottom_{\ SC} \\ \hline Emission \ Ratio_{\ Sample} - Bottom_{\ SC} \end{array} \right) - 1 \land \left(\begin{array}{c} 1 \\ \hline Hillslope_{\ SC} \end{array} \right) \end{array} \right\} * 100$				
% Inhibition	\[\begin{pmatrix} \ 1 - \frac{\% \text{Conversion }_{Sample}}{\% \text{Conversion }_{0\% \text{Inhibition Ctrl}}} \end{pmatrix} \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \				
Difference Between Data Points (single point only)	% Inhibition Point 1 - % Inhibition Point 2				
Test Compound Interference	For each emission wavelength, fluorescence interference is flagged for a compound well that is more than 20% outside the range of the controls.				
Z ' (using Emission Ratio values)	1 - 3 * Stdev \(_{0\% \conv \c				

^{*} SC = Standard Curve

Graphing Software

SelectScreen Kinase Profiling Service uses XL*fit* from IDBS. The ATP/ADP standard curve is fit to model number 205 (sigmoidal dose-response model). The dose response curve is also curve fit to model number 205. If the bottom of the curve does not fit between -20% & 20% inhibition, it is set to 0% inhibition. If the top of the curve does not fit between 70% and 130% inhibition, it is set to 100% inhibition.



Adapta[™] Screening Protocol and Assay Conditions
Revised 19-Jun-2017

Page 6 of 11

Kinase-Specific Assay Conditions

Note about Lipid Substrates

Lipid substrates are prepared by creating lipid vesicles. In some cases, these vesicles include a carrier lipid, such as phosphatidylserine (PS). In the assay conditions section below, "PIP2:PS" refers to large unilamellar vesicles (LUVs) containing five mole percent L- α -Phosphatidylinositol-4,5-bisphosphate and ninety-five percent phosphatidylserine. The concentration listed refers only to the PIP2 substrate, not the PS carrier lipid.

CAMK1 (CaMK1)

The 2X CAMK1 (CaMK1) / ZIPtide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 1.58 - 12 ng CAMK1 (CaMK1) and 200 μ M ZIPtide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 500 μ M EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

CDK4/cyclin D1

The 2X CDK4/cyclin D1 / Rb Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 7.5 - 30 ng CDK4/cyclin D1 and 1 μ M Rb Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added

CDK4/cyclin D3

The 2X CDK4/cyclin D3 / Rb Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 12.5 - 50 ng CDK4/cyclin D3 and 1 μ M Rb Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

CDK6/cyclin D1

The 2X CDK6/cyclin D1 / Rb Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 1.75 - 7 ng CDK6/cyclin D1 and 1 μ M Rb Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

CDK7/cyclin H/MNAT1

The 2X CDK7/cyclin H/MNAT1 / CDK7/9tide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.87 - 38.75 ng CDK7/cyclin H/MNAT1 and 200 μM CDK7/9tide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

CDK9/cyclin T1

The 2X CDK9/cyclin T1 / CDK7/9tide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 4 - 40 ng CDK9/cyclin T1 and 200 μ M CDK7/9tide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

CHUK (IKK alpha)

The 2X CHUK (IKK alpha) is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 15 - 120 ng CHUK (IKK alpha) in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. No substrate is required, as this assay measures the ability of a compound to inhibit the kinase's intrinsic ATPase activity. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

DAPK1

The 2X DAPK1 / ZIPtide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.22 - 5.4 ng DAPK1 and 200 μM ZIPtide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 500 μM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.



Adapta™ Screening Protocol and Assay Conditions

Revised 19-Jun-2017

Page 7 of 11

GSG2 (Haspin)

The 2X GSG2 (Haspin) / Histone H3 (1-20) peptide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.1 - 1.4 ng GSG2 (Haspin) and 100 µM Histone H3 (1-20) peptide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

IRAK1

The 2X IRAK1 / Histone H3 (1-20) peptide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 3.17 - 30.5 ng IRAK1 and 100 μ M Histone H3 (1-20) peptide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

LRRK2

The 2X LRRK2 / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 3.75 - 70 ng LRRK2 and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

LRRK2 FL

The 2X LRRK2 FL / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 5 - 70 ng LRRK2 FL and 200 μ M ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

LRRK2 G2019S

The 2X LRRK2 G2019S / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3 - 12 ng LRRK2 G2019S and 200 μM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

LRRK2 G2019S FL

The 2X LRRK2 G2019S FL / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 2.5 - 25 ng LRRK2 G2019S FL and 200 μ M ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

LRRK2 I2020T

The 2X LRRK2 I2020T / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 4 - 110 ng LRRK2 I2020T and 200 µM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of Detection Mix is added.

LRRK2 R1441C

The 2X LRRK2 R1441C / ERM (LRRKtide) mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 7.5 - 60 ng LRRK2 R1441C and 200 μM ERM (LRRKtide) in 25 mM Tris / 7.5 mM HEPES pH 8.2, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

NUAK1 (ARK5)

The 2X NUAK1 (ARK5) / CHKtide mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 2.5 - 30 ng NUAK1 (ARK5) and 200 μ M CHKtide in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PI4K2A (PI4K2 alpha)

The 2X PI4K2A (PI4K2 alpha) / PI Lipid Kinase Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 7.5 - 40 ng PI4K2A (PI4K2 alpha) and 100 μ M PI Lipid Kinase Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PI4K2B (PI4K2 beta)

The 2X PI4K2B (PI4K2 beta) / PI Lipid Kinase Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μ L Kinase Reaction consists of 3.75 - 20 ng PI4K2B (PI4K2 beta) and 100 μ M PI Lipid Kinase Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MnCl2, 0.5 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.



Adapta™ Screening Protocol and Assay Conditions

Revised 19-Jun-2017

Page 8 of 11

PI4KA (PI4K alpha)

The 2X PI4KA (PI4K alpha) / PI Lipid Kinase Substrate mixture is prepared in 20 mM Tris, pH 7.5, 0.4% Triton X-100, 5 mM MgCl2, 0.5 mM EGTA. The final 10 μL Kinase Reaction consists of 75 - 300 ng PI4KA (PI4K alpha) and 100 μM PI Lipid Kinase Substrate in 7.5 mM HEPES, 10 mM Tris, pH 7.5, 0.2% Triton X-100, 2.5 mM MgCl2, 0.25 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PI4KB (PI4K beta)

The 2X PI4KB (PI4K beta) / PI Lipid Kinase Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.1% CHAPS, 1 mM EGTA, 4 mM MgCl2. The final 10 μL Kinase Reaction consists of 3.75 - 60 ng PI4KB (PI4K beta) and 100 μM PI Lipid Kinase Substrate in 32.5 mM HEPES pH 7.5, 0.05% CHAPS, 0.5 mM EGTA, 2 mM MgCl2. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIK3C2A (PI3K-C2 alpha)

The 2X PIK3C2A (PI3K-C2 alpha) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 μ L Kinase Reaction consists of 10 - 120 ng PIK3C2A (PI3K-C2 alpha) and 100 μ M PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PIK3C2B (PI3K-C2 beta)

The 2X PIK3C2B (PI3K-C2 beta) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 μL Kinase Reaction consists of 50 - 250 ng PIK3C2B (PI3K-C2 beta) and 100 μM PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIK3C2G (PI3K-C2 gamma)

The 2X PIK3C2G (PI3K-C2 gamma) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 μL Kinase Reaction consists of 1 - 28 ng PIK3C2G (PI3K-C2 gamma) and 100 μM PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIK3C3 (hVPS34)

The 2X PIK3C3 (hVPS34) / PI Lipid Kinase Substrate mixture is prepared in 100 mM HEPES pH 7.5, 0.2% CHAPS, 10 mM MnCl2, 2 mM EGTA. The final 10 μL Kinase Reaction consists of 2 - 38.65 ng PIK3C3 (hVPS34) and 100 μM PI Lipid Kinase Substrate in 57.5 mM HEPES pH 7.5, 0.1% CHAPS, 5 mM MnCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha)

The 2X PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha) / PIP2:PS mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 μ L Kinase Reaction consists of 15 - 60 ng PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha) and 50 μ M PIP2:PS in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha)

The 2X PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1 - 8 ng PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha) and 50 μ M PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PIK3CA/PIK3R1 (p110 alpha/p85 alpha)

The 2X PIK3CA/PIK3R1 (p110 alpha/p85 alpha) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.25 - 2 ng PIK3CA/PIK3R1 (p110 alpha/p85 alpha) and 50 μ M PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PIK3CA/PIK3R3 (p110 alpha/p55 gamma)

The 2X PIK3CA/PIK3R3 (p110 alpha/p55 gamma) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 1.25 - 12 ng PIK3CA/PIK3R3 (p110 alpha/p55 gamma) and 50 μ M PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.



Adapta™ Screening Protocol and Assay Conditions

Revised 19-Jun-2017

Page 9 of 11

PIK3CB/PIK3R1 (p110 beta/p85 alpha)

The 2X PIK3CB/PIK3R1 (p110 beta/p85 alpha) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 6.25 - 80 ng PIK3CB/PIK3R1 (p110 beta/p85 alpha) and 50 μM PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIK3CB/PIK3R2 (p110 beta/p85 beta)

The 2X PIK3CB/PIK3R2 (p110 beta/p85 beta) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 4.5 - 60 ng PIK3CB/PIK3R2 (p110 beta/p85 beta) and 50 μ M PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PIK3CD/PIK3R1 (p110 delta/p85 alpha)

The 2X PIK3CD/PIK3R1 (p110 delta/p85 alpha) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 3 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.3 - 3 ng PIK3CD/PIK3R1 (p110 delta/p85 alpha) and 50 μ M PIP2:PS in 32.5 mM HEPES pH 7.5, 50 mM NaCl, 0.015% CHAPS, 1.5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PIK3CG (p110 gamma)

The 2X PIK3CG (p110 gamma) / PIP2:PS mixture is prepared in 50 mM HEPES pH 7.5, 1 mM EGTA, 3 mM MgCl2. The final 10 μ L Kinase Reaction consists of 6.25 - 40 ng PIK3CG (p110 gamma) and 50 μ M PIP2:PS in 32.5 mM HEPES pH 7.5, 0.5 mM EGTA, 1.5 mM MgCl2. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

PIP4K2A

The 2X PIP4K2A / PI(5)P mixture is prepared in 50 mM HEPES pH 7.5, 0.1% CHAPS, 1 mM EGTA, 4 mM MgCl2. The final 10 μL Kinase Reaction consists of 1.5 - 6 ng PIP4K2A and 50 μM PI(5)P in 32.5 mM HEPES pH 7.5, 0.05% CHAPS, 0.5 mM EGTA, 2 mM MgCl2. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIP5K1A

The 2X PIP5K1A / PI(3;4)P2 mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 μL Kinase Reaction consists of 2.5 - 10 ng PIP5K1A and 50 μM PI(3;4)P2 in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIP5K1B

The 2X PIP5K1B / PI(3;4)P2 mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 μL Kinase Reaction consists of 15 - 60 ng PIP5K1B and 50 μM PI(3;4)P2 in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

PIP5K1C

The 2X PIP5K1C / PI(3;4)P2 mixture is prepared in 100 mM HEPES pH 7.5, 200 mM NaCl, 0.06% CHAPS, 2 mM EGTA, 6 mM MgCl2, 4 mM DTT. The final 10 μL Kinase Reaction consists of 3 - 12 ng PIP5K1C and 50 μM PI(3;4)P2 in 57.5 mM HEPES pH 7.5, 100 mM NaCl, 0.03% CHAPS, 1 mM EGTA, 3 mM MgCl2, 2 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of Detection Mix is added.

SPHK1

The $\overline{2X}$ SPHK1 / Sphingosine Lipid Substrate mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μ L Kinase Reaction consists of 0.05 - 1.1 ng SPHK1 and 50 μ M Sphingosine Lipid Substrate in 32.5 mM HEPES pH 7.5, 0.005% BRIJ-35, 5 mM MgCl2, 0.5 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.

SPHK2

The 2X SPHK2 / Sphingosine Lipid Substrate mixture is prepared in 50 mM HEPES pH 7.5, 1 mM EGTA, 3 mM MgCl2. The final 10 μ L Kinase Reaction consists of 40 - 250 ng SPHK2 and 50 μ M Sphingosine Lipid Substrate in 32.5 mM HEPES pH 7.5, 0.5 mM EGTA, 1.5 mM MgCl2. After the 1 hour Kinase Reaction incubation, 5 μ L of Detection Mix is added.



Adapta[™] Screening Protocol and Assay Conditions
Revised 19-Jun-2017

Page 10 of 11

Table of Kinase ATP Km Bins and Inhibitor Validation

The table below provides specifications and data around each kinase. The representative IC50 value with a known inhibitor for each kinase was determined at the ATP bin nearest to the ATP Km app, unless indicated with an asterisk (*) in which case the IC50 value was determined at 10 μ M ATP.

Kinase	Substrate	ATP Km app (μM)	ATP Bin (μM)	Inhibitor	IC50 (nM)	
CAMK1 (CaMK1)	ZIPtide	845	N/A	Staurosporine	3.61	*
CDK4/cyclin D1	Rb Substrate	1	N/A	Staurosporine	66.1	*
CDK4/cyclin D3	Rb Substrate	1	N/A	Staurosporine	68.7	*
CDK6/cyclin D1	Rb Substrate	1	N/A	Staurosporine	11.8	*
CDK7/cyclin H/MNAT1	CDK7/9tide	153	150	Staurosporine	36.9	
CDK9/cyclin T1	CDK7/9tide	32	25	Staurosporine	4.52	
CHUK (IKK alpha)	None	8.8	10	Staurosporine	36.6	
DAPK1	ZIPtide	5.8	5	Staurosporine	2.34	
GSG2 (Haspin)	Histone H3 (1-20) peptide	32	25	Staurosporine	5.39	
IRAK1	Histone H3 (1-20) peptide	36.5	25	Staurosporine	21.1	
LRRK2	ERM (LRRKtide)	70	75	Staurosporine	1.51	
LRRK2 FL	ERM (LRRKtide)	44	50	Staurosporine	1.28	
LRRK2 G2019S	ERM (LRRKtide)	100	100	Staurosporine	0.601	
LRRK2 G2019S FL	ERM (LRRKtide)	134	150	Staurosporine	0.802	
LRRK2 I2020T	ERM (LRRKtide)	7.5	10	Staurosporine	0.862	
LRRK2 R1441C	ERM (LRRKtide)	60	50	Staurosporine	1.94	
NUAK1 (ARK5)	CHKtide	35	25	Staurosporine	2.53	
PI4K2A (PI4K2 alpha)	PI Lipid Kinase Substrate	2	5	Staurosporine	13900	
PI4K2B (PI4K2 beta)	PI Lipid Kinase Substrate	4	5	None		
PI4KA (PI4K alpha)	PI Lipid Kinase Substrate	132	N/A	None		*
PI4KB (PI4K beta)	PI Lipid Kinase Substrate	6.7	5	PIK-93	6.06	
PIK3C2A (PI3K-C2 alpha)	PI Lipid Kinase Substrate	19	25	PI-103	129	
PIK3C2B (PI3K-C2 beta)	PI Lipid Kinase Substrate	150	N/A	PI-103	4.30	*
PIK3C2G (PI3K-C2 gamma)	PI Lipid Kinase Substrate	128	150	PI-103	11.9	
PIK3C3 (hVPS34)	PI Lipid Kinase Substrate	9.3	10	PIK-93	1190	
PIK3CA E542K/PIK3R1 (p110 alpha E542K/p85 alpha)	PIP2:PS	1	N/A	PI-103	3.36	*
PIK3CA E545K/PIK3R1 (p110 alpha E545K/p85 alpha)	PIP2:PS	98	100	PI-103	6.15	
PIK3CA/PIK3R1 (p110	PIP2:PS	25	25	PI-103	4.14	



Adapta[™] Screening Protocol and Assay Conditions Revised 19-Jun-2017

Page 11 of 11

alpha/p85 alpha)						
PIK3CA/PIK3R3 (p110 alpha/p55 gamma)	PIP2:PS	77	75	PI-103	5.78	
PIK3CB/PIK3R1 (p110 beta/p85 alpha)	PIP2:PS	166	150	PI-103	14.0	
PIK3CB/PIK3R2 (p110 beta/p85 beta)	PIP2:PS	171	150	PI-103	19.5	
PIK3CD/PIK3R1 (p110 delta/p85 alpha)	PIP2:PS	63	75	PI-103	6.30	
PIK3CG (p110 gamma)	PIP2:PS	31	25	PI-103	32.2	
PIP4K2A	PI(5)P	1	N/A	Staurosporine	21000	*
PIP5K1A	PI(3;4)P2	1	N/A	Staurosporine	6220	*
PIP5K1B	PI(3;4)P2	1	N/A	Staurosporine	6060	*
PIP5K1C	PI(3;4)P2	1	N/A	Staurosporine	1150	*
SPHK1	Sphingosine Lipid Substrate	10.3	10	JAK3 Inhibitor V	6790	
SPHK2	Sphingosine Lipid Substrate	214	N/A	JAK3 Inhibitor V	1430	*